Form 13-F position report

VENTYX BIOSCIENCES INC

Reported by MORGAN STANLEY

VTYX CUSIP 92332V107 Manager CIK 0000895421

Reported 514,291 shares, down 81,585 (13.7%) from the prior quarter.

Reported value -15.5%; share count -13.7% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2023
Shares 514,291 Quarter-end amount reported
Reported value $16,868,745 Fair value at quarter end
Consecutive quarters held 7 Through Q2 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 135000
2022-03-31 90000
2022-06-30 234000
2022-09-30 2887000
2022-12-31 3909027
2023-03-31 19961849
2023-06-30 16868745
2023-09-30 9867036
2023-12-31 4730113
2024-03-31 7338861
2024-06-30 1457095
2024-09-30 725237
2024-12-31 5498818
2025-03-31 1007583
2025-06-30 1114979
2025-09-30 758084
2025-12-31 38765348
2026-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

18 quarters
Quarterly reported position history for VENTYX BIOSCIENCES INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2026 Reduced 0 -4,292,951 (-100.0%) 0 $0 2026-05-15
Q4 2025 Added 4,292,951 +4,049,194 (1661.2%) < 0.01% $38,765,348 2026-02-13
Q3 2025 Reduced 243,757 -277,261 (-53.2%) < 0.01% $758,084 2025-11-14
Q2 2025 Reduced 521,018 -355,142 (-40.5%) < 0.01% $1,114,979 2025-08-15
Q1 2025 Reduced 876,160 -1,634,716 (-65.1%) < 0.01% $1,007,583 2025-05-15
Q4 2024 Added 2,510,876 +2,178,199 (654.7%) < 0.01% $5,498,818 2025-02-14
Q3 2024 Reduced 332,677 -298,100 (-47.3%) < 0.01% $725,237 2024-11-14
Q2 2024 Reduced 630,777 -703,561 (-52.7%) < 0.01% $1,457,095 2024-08-14
Q1 2024 Reduced 1,334,338 -580,688 (-30.3%) < 0.01% $7,338,861 2024-05-15
Q4 2023 Added 1,915,026 +1,630,919 (574.1%) < 0.01% $4,730,113 2024-02-13
Q3 2023 Reduced 284,107 -230,184 (-44.8%) < 0.01% $9,867,036 2023-11-15
Q2 2023 Reduced 514,291 -81,585 (-13.7%) < 0.01% $16,868,745 2023-08-14
Q1 2023 Added 595,876 +476,662 (399.8%) < 0.01% $19,961,849 2023-05-15
Q4 2022 Added 119,214 +36,464 (44.1%) < 0.01% $3,909,027 2023-02-14
Q3 2022 Added 82,750 +63,614 (332.4%) < 0.01% $2,887,000 2022-11-14
Q2 2022 Added 19,136 +12,512 (188.9%) < 0.01% $234,000 2022-08-15
Q1 2022 Reduced 6,624 -162 (-2.4%) < 0.01% $90,000 2022-05-13
Q4 2021 New 6,786 +6,786 (0.0%) < 0.01% $135,000 2022-02-14

Who else reported the position

176 managers reported VENTYX BIOSCIENCES INC for Q2 2023.

Managers reporting VENTYX BIOSCIENCES INC in Q2 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Added 8,553,231 +948,890 0.02% $280,545,977 7 qtrs
PRICE T ROWE ASSOCIATES INC MD Added 3,949,293 +1,263,761 0.02% $129,538,000 4 qtrs
BlackRock Inc Added 3,226,572 +1,177,971 < 0.01% $105,831,562 7 qtrs
CITADEL ADVISORS LLC Reduced 2,787,132 -226,891 0.02% $91,417,930 7 qtrs
Capital International Investors Added 2,727,852 +350,068 0.02% $89,473,546 3 qtrs
VANGUARD GROUP INC Added 2,384,765 +577,060 < 0.01% $78,220,292 7 qtrs
LORD ABBETT & CO LLC Added 2,317,175 +998,782 0.26% $76,003,000 4 qtrs
JANUS HENDERSON GROUP PLC Added 1,766,307 +167,891 0.04% $57,926,849 7 qtrs
The Goldman Sachs Group Inc Added 1,567,820 +217,280 0.01% $51,424,496 5 qtrs
Holocene Advisors LP Added 1,537,084 +500,571 0.22% $50,416,355 3 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2023
Filed
August 14, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
505,087
Shared
408
None
8,796

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.